INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024 Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as...

INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer Represents First Ever Natural Killer Immunotherapy trial in Metastatic Castration-Resistant Prostate CancerWebinar at 11AM ET on Friday, May 12. BOCA RATON, Fla., May 08, 2023 (GLOBE...

INmune Bio to Present at BIO CEO & Investor Conference LA JOLLA, CA, Feb. 06, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (Nasdaq: INMB) (“INmune” or the “Company”), an immunotherapy company focused on developing therapies that harness the patient’s...

INmune Bio Announces Publication of Myeloid-Derived Suppressor Cells (MDSC) Report in the Cell’s Trends in Pharmacological Sciences Journal Manuscript highlights the vital role of MDSC in the tumor microenvironment (TME) LA JOLLA, Calif.,, Dec. 07, 2018 (GLOBE NEWSWIRE) --  INmune Bio Inc., an immunotherapy company developing...

INmune Nominated for Buzz of Bio Award at 2019 CEO & Investor Conference -Voting begins today: Click here to cast your vote- LA JOLLA, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunotherapy company focused on developing therapies that harness...